Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Dec;150(6):1610-9.e13.
doi: 10.1016/j.jtcvs.2015.06.044. Epub 2015 Jun 30.

Propofol cardioplegia: A single-center, placebo-controlled, randomized controlled trial

Chris A Rogers  1 , Alan J Bryan  2 , Rachel Nash  3 , M Saadeh Suleiman  2 , Sarah Baos  3 , Zoe Plummer  3 , James Hillier  2 , Ian Davies  2 , Richard Downes  2 , Eamonn Nicholson  2 , Barnaby C Reeves  3 , Gianni D Angelini  2
Affiliations
Free article
Randomized Controlled Trial

Propofol cardioplegia: A single-center, placebo-controlled, randomized controlled trial

Chris A Rogers et al. J Thorac Cardiovasc Surg. 2015 Dec.
Free article

Abstract

Objectives: Cardiac surgery with cardiopulmonary bypass and cardioplegic arrest is an effective treatment for coronary artery and aortic valve diseases. However, the myocardium sustains reperfusion injury after ischemic cardioplegic arrest. Our objective was to assess the benefits of supplementing cardioplegia solution with the general anesthetic propofol in patients undergoing either coronary artery bypass grafting (CABG) or aortic valve replacement (AVR).

Methods: A single-center, double-blind randomized controlled trial was carried out to compare cardioplegia solution supplemented with propofol (concentration 6 μg/mL) versus intralipid (placebo). The primary outcome was cardiac troponin T release over the first 48 hours after surgery.

Results: We recruited 101 participants (51 in the propofol group, 50 in the intralipid group); 61 underwent CABG and 40 underwent AVR. All participants were followed to 3 months. Cardiac troponin T release was on average 15% lower with propofol supplementation (geometric mean ratio, 0.85; 95% confidence interval [CI], 0.73-1.01; P = .051). There were no differences for CABG participants but propofol-supplemented participants undergoing AVR had poorer postoperative renal function (geometric mean ratio, 1.071; 95% CI, 1.019-1.125; P = .007), with a trend toward longer intensive care stay (median, 89.5 vs 47.0 hours; hazard ratio, 0.58; 95% CI, 0.31-1.09; P = .09) and fewer with perfect health (based on the EQ-5D health utility index) at 3 months (odds ratio, 0.26; 95% CI, 0.06-1.05; P = .058) compared with the intralipid group. Safety profiles were similar. There were no deaths.

Conclusions: Propofol supplementation in cardioplegia appears to be cardioprotective. Its influence on early clinical outcomes may differ between CABG and AVR surgery. A larger, multicenter study is needed to confirm or refute these suggestions.

Keywords: AVR; CABG; cardioplegia; cardiopulmonary bypass; propofol.

PubMed Disclaimer

Comment in

Publication types

MeSH terms